| UHC UMR Medical and Drug | Percutaneous Patent Foramen Ovale (PFO) Closure – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Plagiocephaly and Craniosynostosis Treatment – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Prolotherapy and Platelet Rich Plasma Therapies – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Rituximab (Riabni®, Rituxan®, Ruxience®, & Truxima®) - Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Roctavian® (Valoctocogene Roxaparvovec-Rvox) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Sacral Nerve Stimulation for Urinary and Fecal Indications – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Sensory Integration Therapy and Auditory Integration Training – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Spinal Fusion and Bone Healing Enhancement Products – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Subcutaneous Implantable Naltrexone Pellets – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Surgery for the Prevention and Treatment of Lymphedema – Commercial and Individual Exchange Medical Policy | 2026-01-01 |